Literature DB >> 1424050

Factors controlling the development of arterial lesions after injury.

M A Reidy1, J Fingerle, V Lindner.   

Abstract

This review discusses the role of growth factors on the proliferation of smooth muscle cells (SMCs) in injured arteries. We have used a variety of procedures to injure rat carotid arteries and noted that removal of endothelium followed by platelet adherence does not always initiate SMC replication. Furthermore, thrombocytopenia did not reduce the early SMC replication induced by balloon catheter injury. Platelet-derived growth factor (PDGF) has been found to exert little effect on SMC replication but markedly influences the ability of SMCs to migrate to the intima. Basic fibroblast growth factor (bFGF) is a potent mitogen for SMCs in denuded arteries while having no effect on cells in control uninjured arteries. We have hypothesized that arterial injury leads to release of bFGF from injured SMCs and so stimulates cell replication. Rats were treated with antibodies to bFGF immediately before balloon injury, and this significantly reduced the SMC replication. These findings suggest that in vivo bFGF is an important mitogen for initiating SMC replication and that PDGF is important as a chemotactic for SMCs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424050

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Dynamics of Vascular Remodeling: An Overview and Bibliography.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  TGF-beta 1 reverses PDGF-stimulated migration of human aortic smooth muscle cells in vitro.

Authors:  L Engel; U Ryan
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-06       Impact factor: 2.416

3.  20-Hydroxyeicosatetraenoic acid inhibition attenuates balloon injury-induced neointima formation and vascular remodeling in rat carotid arteries.

Authors:  Ludwig D Orozco; Huiling Liu; Eddie Perkins; Daryl A Johnson; Betty B Chen; Fan Fan; Rodney C Baker; Richard J Roman
Journal:  J Pharmacol Exp Ther       Date:  2013-05-08       Impact factor: 4.030

4.  Dual antiplatelet and anticoagulant APAC prevents experimental ischemia-reperfusion-induced acute kidney injury.

Authors:  Raimo Tuuminen; Annukka Jouppila; Dan Salvail; Charles-E Laurent; Marie-Claude Benoit; Simo Syrjälä; Heikki Helin; Karl Lemström; Riitta Lassila
Journal:  Clin Exp Nephrol       Date:  2016-07-12       Impact factor: 2.801

5.  Basic fibroblast growth factor regulates extracellular matrix and contractile protein expression independent of proliferation in vascular smooth muscle cells.

Authors:  S Kato; A Muraishi; T Miyamoto; J C Fox
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-04       Impact factor: 2.416

6.  Characterization of Pdgfrb-Cre transgenic mice reveals reduction of ROSA26 reporter activity in remodeling arteries.

Authors:  Anne S Cuttler; Renée J LeClair; J Patrizia Stohn; Qiaozeng Wang; Christine M Sorenson; Lucy Liaw; Volkhard Lindner
Journal:  Genesis       Date:  2011-07-22       Impact factor: 2.487

7.  Phenotypic transformation and migration of adventitial cells following angioplasty.

Authors:  Yong-Li Wang; Li-Zhen Liu; Zhong-Hui He; Kun-Hong Ding; Feng Xue
Journal:  Exp Ther Med       Date:  2012-04-17       Impact factor: 2.447

8.  The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice.

Authors:  Gianluca Grassia; Marcella Maddaluno; Angelo Guglielmotti; Giorgina Mangano; Giuseppe Biondi; Pasquale Maffia; Armando Ialenti
Journal:  Cardiovasc Res       Date:  2009-07-10       Impact factor: 10.787

9.  Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair.

Authors:  Jitka Ismail Virag; Charles E Murry
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

Review 10.  Intimal hyperplasia in murine models.

Authors:  David Y Hui
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.